Toujeo Pediatric Indication Approved in US
The FDA has approved an expanded indication for Sanofi’s Toujeo in pediatric patients aged 6 years and older based on the positive results from EDITION JUNIOR, which were announced earlier this month. Previously, Toujeo was only approved for adults aged 18 and over. A Sanofi press release has not yet been observed. Below, FENIX provides context and insights on the expanded indication.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.